Table 1 Baseline characteristics
N (%) | |
|---|---|
Number of patients | 20 |
Age—median (IQR) | 62.5 (58–74) |
Male gender | 11 (55%) |
Years since diagnosis—median (IQR) | 4.3 (1.5–11.8) |
ECOG PS | |
0 | 13 (65%) |
1 | 7 (35%) |
Functional tumor | 7 (35%) |
MEN1 | 4 (20%) |
Hepatic tumor burden | |
< 25% | 14 (70%) |
> 25% | 6 (30%) |
Baseline chromogranin A—median (IQR) | 580 (183.5–1811) |
Type of tumor | |
Intestine | 9 (45%) |
Pancreas | 4 (20%) |
Insulinoma | 2 (10%) |
Gastrinoma | 1 (5%) |
Lung | 1 (5%) |
VIPoma | 1 (5%) |
Unknown | 2 (10%) |
WHO grade | |
1 | 7 (35%) |
2 | 10 (50%) |
3 | 3 (15%) |
Tissue involvement | |
Liver | 18 (90%) |
Lymph nodes | 12 (60%) |
Bone | 5 (25%) |
Previous treatments | |
SSA | 17 (85%) |
Surgery | 9 (45%) |
SIRT | 4 (20%) |
Chemotherapy | 1 (5%) |
External-beam radiotherapy | 1 (5%) |
Mean pre-SUV-lbmliver (sd) | 4.61 (± 2.24) |
Mean post-SUV-lbmliver (sd) | 3.90 (± 1.79) |